Germin8 Ventures today announced the appointment of physician-scientist Dr. Ashlie L Burkart, MD as Chief Scientific Officer.
As an clinical pathologist with expertise in gastrointestinal/liver pathology, Dr. Burkart is skilled at diagnosing and investigating the nature of gastrointestinal diseases, as well as the laboratory application of biologic, chemical and physical sciences. Since this skill set could be used towards health and nutrition, microbiome, agro-ecology, and climate alike, Dr. Burkart joins Germin8 effectively as a medical-ecologist bringing intellectual horsepower to shepherd a new standard of care for people and the planet, enabled by our food.
“Dr. Burkart has the potential to be effective for a vast population by engaging farm-to-fork. As health paradigms shift and the worlds of food, agriculture and medicine converge, Dr. Burkart’s profile is exactly what we need to see more of in our ecosystem to bust myths, challenge conventional thought, illuminate pathways for viable impact and bridge scientific and non-scientific communities effectively,” said Michael Lavin, Founder & Managing Partner, Germin8 Ventures. “We're honored to lead this charge with Dr. Burkart, who will contribute meaningfully to investment strategy, deal sourcing and evaluation while adding value to founders as an expert thought partner guiding strategy, advising de-risking and contributing to company building.”
"Now that abundant scientific data shows diet and the state of the gut microbiome are key to human health, bringing together medical science with agri-food tech will result in a collaboration worth far more than the sum of its parts,” said Dr. Burkart. “I am honored to join Germin8’s team and be a part of their effort to make a more substantial impact on health and the environment.”
For more information: